Be Ready for Updated mRNA COVID-19 Vaccines
It’ll be all hands on deck for 2023-2024 COVID-19 vaccines.
Moderna and Pfizer’s mRNA vaccines (Spikevax XBB.1.5, Comirnaty Omicron XBB.1.5) are now approved as MONOvalent vaccines covering the Omicron XBB.1.5 SARS-CoV-2 subvariant...for patients down to 6 months.
Health Canada is also reviewing Novavax’s COVID-19 monovalent vaccine for 12 years and up...also targeting the XBB.1.5 subvariant.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive